Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 580,403,456
  • Shares Outstanding, K 2,408,613
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,550 M
  • EBITDA $ 38,053 M
  • 60-Month Beta 0.34
  • Price/Sales 6.21
  • Price/Cash Flow 17.21
  • Price/Book 7.18

Options Overview Details

View History
  • Implied Volatility 28.53% (+0.99%)
  • Historical Volatility 14.79%
  • IV Percentile 97%
  • IV Rank 70.85%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 3) 7.99 (3.37%)
  • Put/Call Vol Ratio 0.83
  • Today's Volume 1,641
  • Volume Avg (30-Day) 15,702
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 362,183
  • Open Int (30-Day) 367,984
  • Expected Range 228.94 to 244.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $2.69
  • Number of Estimates 8
  • High Estimate $2.85
  • Low Estimate $2.41
  • Prior Year $2.77
  • Growth Rate Est. (year over year) -2.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
232.24 +2.54%
on 03/24/26
247.21 -3.67%
on 04/02/26
-2.26 (-0.94%)
since 03/06/26
3-Month
203.85 +16.82%
on 01/12/26
251.71 -5.39%
on 03/02/26
+30.65 (+14.77%)
since 01/07/26
52-Week
141.50 +68.30%
on 04/09/25
251.71 -5.39%
on 03/02/26
+87.52 (+58.11%)
since 04/07/25

Most Recent Stories

More News
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

The VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiency i,ii VARIPULSE Pro to be featured...

JNJ : 238.53 (-1.01%)
Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

ABT : 102.01 (-0.28%)
JNJ : 238.53 (-1.01%)
This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion,...

ABT : 102.01 (-0.28%)
JNJ : 238.53 (-1.01%)
MDT : 85.96 (-0.37%)
$INX : 6,559.68 (-0.79%)
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies

JNJ : 238.53 (-1.01%)
A Q2 2026 Playbook for Navigating Market Uncertainty

For investors looking to rebalance in Q2, here are three stocks that combine growth and defense to help investors stay invested during volatile markets

MSFT : 368.35 (-1.21%)
JNJ : 238.53 (-1.01%)
NEE : 92.51 (-0.24%)
What You Need To Know Ahead of Johnson & Johnson's Earnings Release

Johnson & Johnson is expected to announce its first-quarter results next month, and analysts are projecting a single-digit decline in its EPS.

XLV : 145.21 (-0.73%)
$SPX : 6,569.44 (-0.64%)
JNJ : 238.53 (-1.01%)
2 Safe Dividend Stocks to Buy and Hold Forever

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

$SPX : 6,569.44 (-0.64%)
PG : 142.36 (-0.29%)
JNJ : 238.53 (-1.01%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 67.27 (+1.08%)
AAPL : 248.86 (-3.86%)
AVGO : 324.59 (+3.23%)
CVX : 204.14 (+2.66%)
VZ : 48.89 (-0.53%)
$SPX : 6,569.44 (-0.64%)
JPM : 294.58 (-0.29%)
JNJ : 238.53 (-1.01%)
SCHD : 30.62 (-0.07%)
ABBV : 201.76 (-2.39%)
BMY : 58.20 (-1.90%)
MSFT : 368.35 (-1.21%)
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill

JNJ : 238.53 (-1.01%)
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

RARITAN, N.J. , March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing...

JNJ : 238.53 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 245.85
2nd Resistance Point 244.68
1st Resistance Point 242.83
Last Price 238.53
1st Support Level 239.81
2nd Support Level 238.64
3rd Support Level 236.79

See More

52-Week High 251.71
Last Price 238.53
Fibonacci 61.8% 209.61
Fibonacci 50% 196.61
Fibonacci 38.2% 183.60
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.